Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name: Name:	
Nard:	NHI:
3endamustir	ne hydrochloride
	reatment naive CLL (tick boxes where appropriate)
and and and and and O an	The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment  The patient is chemotherapy treatment naive  The patient is unable to tolerate toxicity of full-dose FCR  Patient has ECOG performance status 0-2  Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6  Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles  lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known production chemotherapy regimen and supportive treatments.
Re-assessment Prerequisites (  and	ndolent, Low-grade lymphomas t required after 9 months (tick boxes where appropriate)  The patient has indolent low grade NHL requiring treatment  Patient has a WHO performance status of 0-2
or	Patient is treatment naive  Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+)  Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen  Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles
or	The patient has not received prior bendamustine therapy  and  Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)  and  Patient has had a rituximab treatment-free interval of 12 months or more
	O Bendamustine is to be administered as monotherapy for a maximum of 6 cycles in rituximab refractory patients

I confirm that the above details are correct:

0:	D - 1 - 1	

## HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

Name:  Ward:  NHI:  Bendamustine hydrochloride - continued  CONTINUATION - Indolent, Low-grade lymphomas Re-assessment required after 6 months  Prerequisites (lick boxes where appropriate)  Patient is refractory to or has relapsed within 12 months of rituximab in combination with bendamustine  Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles  or  Patients have not received a bendamustine regimen within the last 12 months  and  Patient has had a rituximab treatment-free interval of 12 months or more  or  Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)  and  Patient has had a rituximab treatment-free interval of 12 months or more  or  Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients  Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.  INITIATION - Hodgkin's lymphoma*  Re-assessment required after 6 months  Prerequisites (lick boxes where appropriate)  Patient has Hodgkin's lymphoma requiring treatment  and  Patient has a ECOG performance status of 0-2  and  Patient has received one prior line of chemotherapy  and  Patient's disease relapsed or was refractory following prior chemotherapy  and  Bendamustine is to be administered in combination with gemotiabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles  Note: Indications marked with * are unapproved indications.	PRESCRIBER	PATIENT:
CONTINUATION – Indolent, Low-grade lymphomas Re-assessment required after 9 months Prerequisites (tick boxes where appropriate)  Patient is refractory to or has relapsed within 12 months of rituximab in combination with bendamustine and Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles  Patients have not received a bendamustine regimen within the last 12 months and Patients have not received a bendamustine regimen within the last 12 months  Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)  Patient has had a rituximab treatment-free interval of 12 months or more  or Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients  Note: "Indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.  INITIATION – Hodgkin's lymphoma* Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)  Patient has Hodgkin's lymphoma requiring treatment and Patient has a ECOG performance status of 0-2  and Patient has received one prior line of chemotherapy  and Patient has received one prior line of chemotherapy  and Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles	Name:	Name:
Re-assesment required after 6 months  Prerequisites (tick boxes where appropriate)  Patient has Hodgkin's lymphoma*  Per-assessment required after 6 months  Prerequisites (tick boxes where appropriate)  Patient has Hodgkin's lymphoma requiring treatment and Patient has a ECOG performance status of 0-2 and Patient's disease relapsed or was refractory following prior chemotherapy and Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of 6 cycles in relapsed patients (in combination with rituximab where CD20+) and Patient has had a rituximab treatment-free interval of 12 months or more  Or Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients  Note: 'Indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.  INITIATION – Hodgkin's lymphoma'  Patient has Hodgkin's lymphoma requiring treatment  And Patient has received one prior line of chemotherapy  Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles	Ward:	NHI:
Re-assessment required after 9 months  Prerequisites (tick boxes where appropriate)  Patient has a ECOG performance status of 0-2 and Patient has a ECOG performance status of 0-2 and Patient has a ECOG performance status of 0-2 and Patient has received one prior line of chemotherapy and Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+) and Patient has had a rituximab treatment-free interval of 12 months or more  Or Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients  Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.  INITIATION – Hodgkin's lymphoma*  Re-assessment required after 6 months  Prerequisites (tick boxes where appropriate)  Patient has a ECOG performance status of 0-2 and Patient has received one prior line of chemotherapy and Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles	<b>Bendamust</b> i	ine hydrochloride - continued
Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles  Patients have not received a bendamustine regimen within the last 12 months  Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)  and Patient has had a rituximab treatment-free interval of 12 months or more  or Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients  Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.  INITIATION – Hodgkin's lymphoma* Re-assessment required after 6 months  Prerequisites (tick boxes where appropriate)  Patient has a ECOG performance status of 0-2  and Patient has received one prior line of chemotherapy  and Patient's disease relapsed or was refractory following prior chemotherapy  and Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles	Re-assessmer	nt required after 9 months
Patients have not received a bendamustine regimen within the last 12 months  Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)  and Patient has had a rituximab treatment-free interval of 12 months or more  or Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients  Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.  INITIATION – Hodgkin's lymphoma* Re-assessment required after 6 months  Prerequisites (tick boxes where appropriate)  Patient has Hodgkin's lymphoma requiring treatment  and Patient has a ECOG performance status of 0-2  and Patient has received one prior line of chemotherapy  and Patient's disease relapsed or was refractory following prior chemotherapy  and Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles		d
rituximab when CD20+) and Patient has had a rituximab treatment-free interval of 12 months or more  or Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients  Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.  INITIATION – Hodgkin's lymphoma* Re-assessment required after 6 months  Prerequisites (tick boxes where appropriate)  Patient has Hodgkin's lymphoma requiring treatment and Patient has a ECOG performance status of 0-2 and Patient has received one prior line of chemotherapy and Patient's disease relapsed or was refractory following prior chemotherapy and Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles		
Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.  INITIATION – Hodgkin's lymphoma* Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)  Patient has Hodgkin's lymphoma requiring treatment and Patient has a ECOG performance status of 0-2 and Patient has received one prior line of chemotherapy and Patient's disease relapsed or was refractory following prior chemotherapy and Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles		rituximab when CD20+) and
INITIATION – Hodgkin's lymphoma* Re-assessment required after 6 months  Prerequisites (tick boxes where appropriate)  O Patient has Hodgkin's lymphoma requiring treatment and O Patient has a ECOG performance status of 0-2 and O Patient has received one prior line of chemotherapy and O Patient's disease relapsed or was refractory following prior chemotherapy and O Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles		
Re-assessment required after 6 months  Prerequisites (tick boxes where appropriate)  Patient has Hodgkin's lymphoma requiring treatment  and Patient has a ECOG performance status of 0-2  and Patient has received one prior line of chemotherapy  and Patient's disease relapsed or was refractory following prior chemotherapy  and Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles	Note: 'indolent	t, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.
and O Patient has a ECOG performance status of 0-2 and O Patient has received one prior line of chemotherapy and O Patient's disease relapsed or was refractory following prior chemotherapy and O Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles	Re-assessmen	nt required after 6 months
Patient has a ECOG performance status of 0-2  and Patient has received one prior line of chemotherapy  and Patient's disease relapsed or was refractory following prior chemotherapy  and Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles	O	Patient has Hodgkin's lymphoma requiring treatment
Patient has received one prior line of chemotherapy  and Patient's disease relapsed or was refractory following prior chemotherapy  and Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles	and	Patient has a ECOG performance status of 0-2
Patient's disease relapsed or was refractory following prior chemotherapy  and  Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles	and	Patient has received one prior line of chemotherapy
O Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles		Patient's disease relapsed or was refractory following prior chemotherapy
Note: Indications marked with * are unapproved indications.	and	
	Note: Indicatio	ons marked with * are unapproved indications.

I confirm that the above details are correct:	
Signed:	Date: